2023-508356-19-00招募中2 期
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients not Previously Treated for Metastatic Pancreatic Adenocarcinoma
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 50
- 试验地点
- 21
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
To evaluate the benefit of the addition of TTX-030 with or without budigalimab to nab-paclitaxel + gemcitabine in the target population
研究设计
- 分配方式
- Randomized
- 主要目的
- Follow up period
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •Subject must weigh ≥35 kg.
- •Resolution of adverse events from any prior chemotherapy, immunotherapy, or prior systemic anticancer therapy, radiotherapy, or surgery to Grade 1 or baseline (except Grade 2 alopecia and Grade 2 sensory neuropathy).
- •Women of childbearing potential and all men must agree to use 2 highly effective methods of contraception through 6 months (180 days) after the last administration of any study treatment. Note: Highly effective contraception methods include total abstinence; female sterilization (tubal ligation, bilateral oophorectomy, and/or hysterectomy); male sterilization (at least 6 months prior to Screening); intrauterine device or intrauterine hormone-releasing system; oral, injected, or implanted hormonal contraception with only progestogen at least 30 days before first dose; AND barrier methods of contraception; oral, injectable, transdermal, or intravaginal combined hormonal contraception with estrogen and progestogen at least 30 days before first dose (Prescribing information should be followed if different from the above).
- •Subjects with history of congestive heart failure must have cardiac echocardiogram (ECHO) or multigated acquisition (MUGA) scan indicating left ventricular ejection fraction ≥45% within 28 days prior to the first dose of study treatment.
- •Required baseline laboratory tests: a. Hematology: absolute neutrophil count (ANC) ≥1.2 k/μL, platelets ≥100 k/μL, hemoglobin (Hgb) ≥9 g/dL b. Coagulation: prothrombin time (PT) and International Normalized Ratio (INR) ≤1.2 x upper limit of normal (ULN), except for subjects receiving anticoagulation; subjects must be on a stable dose of warfarin for 6 weeks prior to enrollment. c. Kidney: Creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) ≥40 mL/min calculated by Cockcroft-Gault or CKD-EPI (Appendix 6) d. Liver: AST and ALT ≤2.5 x ULN (or ≤5 x ULN with hepatic metastases); total bilirubin ≤2 x ULN (or ≤3 x ULN with Gilbert’s syndrome); serum albumin ≥3.0 g/dL
- •Male or female subjects ≥18 years of age at the time of screening.
- •Histologically or cytologically confirmed diagnosis of metastatic PDAC.
- •No prior systemic treatment for metastatic disease. Prior neoadjuvant or adjuvant systemic chemotherapy is permitted in the absence of disease progression within 6 months following last dose of chemotherapy.
- •No prior treatment with therapeutics specifically targeted to enhancing or de-repressing anti-tumor immunity including but not limited to checkpoint inhibitors or agents targeting the adenosine pathway (CD39, CD73 or adenosine receptor inhibitors).
- •Evidence of measurable disease as assessed by the investigator per RECIST 1.
- •Appropriate for treatment with nab-paclitaxel and gemcitabine chemotherapy.
- •Availability of tumor tissue (obtained by biopsy during screening, or archival if collected within 90 days prior to the first dose of study drug and in the absence of intervening therapy). Subjects with contraindications for a biopsy procedure and without acceptable archival tissue samples are not eligible.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
排除标准
- •History of clinically significant allergy or hypersensitivity to planned study treatment components or to any monoclonal antibody (defined as any Grade 3 reaction lasting ≥48 hours despite optimal therapy)
- •Subject has received live vaccine within 28 days prior to the first dose of study drug
- •The subject has had major surgery per the Investigator within 28 days prior to the first dose of study drug, and the surgical wound is not adequately healed. A diagnostic or research biopsy does not exclude subjects from enrollment. Placement of a vascular access device such as a Port-A-Cath is not considered major surgery.
- •Has uncontrolled intercurrent illness including, but not limited to: a. Uncontrolled diabetes b. New York Heart Association (NYHA) Class 3 or 4 congestive heart failure c. Unstable angina, arrhythmia, or myocardial infarction within 6 months prior to screening d. Poorly controlled hypertension, defined as a blood pressure consistently above 160/90 mmHg despite optimal medical management e. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days. Indwelling drainage catheters (e.g., PleurX®) are allowed f. Active or chronic viral hepatitis B or C infection g. Uncontrolled thyroid disease h. Active infection requiring systemic therapy; subjects receiving ongoing systemic antibiotic, antiviral or antifungal therapy for maintenance should be discussed with the medical monitor prior to screening and enrollment
- •History of SJS, Toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS)
- •History of autoimmune disease including but not limited to rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, non-infectious pneumonitis, interstitial lung disease (ILD), requiring systemic treatment that required systemic steroids or immunosuppressive agents within the last 2 years. Subjects with findings consistent with active autoimmune disease on screening evaluation (computed tomography [CT] showing pneumonitis or ILD, physical examination findings) are not eligible. NOTE: History of vitiligo, autoimmune thyroiditis, or mild psoriasis are allowed.
- •Any active disease requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to Day 1 of treatment. (NOTE: Inhaled, intranasal, intra-articular and topical [including ocular] steroids are allowed. Adrenal replacement [i.e., physiologic replacement] doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease).
- •History of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, or previous clinical diagnosis of tuberculosis
- •Use of investigational agent within 14 days prior to the first dose of study drug
- •Evidence of active central nervous system (CNS) metastatic disease or carcinomatous meningitis
- •Known history of human immunodeficiency virus (HIV) or other chronic immunodeficiency
- •Women who are pregnant or breastfeeding
结局指标
主要结局
Progression-free survival (PFS)
Progression-free survival (PFS)
次要结局
- Progression-free survival, Objective response rate, Duration of response, Overall survival (PFS, ORR, DoR, OS)
- Type, severity, and frequency of treatment-emergent AEs
研究者
Siddhartha Mitra, MD PHD, Chief Medical Officer
Scientific
Trishula Therapeutics Inc.
研究点 (21)
Loading locations...
相似试验
已完成
2 期
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)Cancer of the BreastEstrogen Receptor- Negative Breast CancerHER2- Negative Breast CancerProgesterone Receptor- Negative Breast CancerRecurrent Breast CancerStage IV Breast CancerTriple-negative Metastatic Breast CancerMetastatic Breast CancerTriple-negative Breast CancerBreast CancerBreast TumorNCT01881230Celgene191
已完成
2 期
Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine CarcinomaNeuroendocrine CarcinomaNCT04705519Peking University79
已完成
3 期
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic AdenocarcinomaCarcinoma, Pancreatic DuctalNCT02993731Sumitomo Pharma America, Inc.1,134
Unknown
2 期
Nab-Paclitaxel Combined With Gemcitabine Adjuvant Chemotherapy After Radical Resection of Intrahepatic CholangiocarcinomaCholangiocarcinoma, IntrahepaticNCT04077983Shanghai Zhongshan Hospital40
撤回
1 期
Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC AdenocarcinomaNSCLC, RecurrentAdenocarcinoma of LungNCT03361319Royal Marsden NHS Foundation Trust